B-cell precursor ALL is a clonal, malignant disease involving blast cells that express antigens such as CD192

  • B-cell precursor ALL is characterized by the accumulation of blast cells that suppresses hematopoiesis
  • CD19 is a cell-surface protein that regulates the immune response3
  • Many B-cell ALL blast cells express CD19, a cell-surface protein expressed on both normal B cells and many B-cell malignancies2
  • CAR T-cell therapy engineers a patient’s own T cells, enabling them to target and kill malignant B cells such as B-cell ALL2,4

TECARTUS is an autologous cellular therapy designed for R/R B-cell ALL, a CD19-expressing B-cell malignancy that contains leukemic blasts1,2

TECARTUS® mechanism of action. TECARTUS® mechanism of action.
  1. Target Binding Domain—binds to CD19 on the surface of B cells1

  2. CD28 Co-stimulatory Domain1

    • CD28 and CD3-ζ, the co-stimulatory domains in TECARTUS, augment T-cell receptor signaling to drive cytokine production and T-cell proliferation
  3. CD3-ζ Activation Domain—activates T cell1

The XLPTM process helps ensure TECARTUS is successfully and reliably manufactured for patients with R/R B-cell ALL5

  • The XLPTM process involves a T-cell selection step that may reduce the likelihood of circulating CD19-expressing tumor cells in patients' leukapheresis material1,5
    • This step was introduced to address the potential risk of premature activation and CAR T-cell exhaustion due to tumor cell exposure during the ex vivo manufacturing process
  • T cells are then transduced with the anti-CD19 CAR transgene1

XLP is a trademark of Kite Pharma, Inc.

TECARTUS is manufactured to remove leukemic blasts found in adult patients with R/R B-cell ALL1

TECARTUS binds to CD19-expressing cancer cells and normal B cells1

TECARTUS® binding to cells.

Upon engagement with target cells, the co-stimulatory domains activate downstream signaling cascades that result in

  • T-cell activation, proliferation, and acquisition of effector functions
  • Secretion of inflammatory cytokines and chemokines
Killing of cells.
This sequence of events leads to the killing of
CD19-expressing cells

Kite is committed to providing rapid turnaround times, reliable manufacturing, and offering convenient apheresis dates to give patients a chance at realizing the benefits of TECARTUS1,6-9

*In the ZUMA-3 trial, 6 patients did not receive TECARTUS due to manufacturing failure.1

Real-world data compiled via Oracle EBS data stored within Kite's Analytics Platform. Data is accurate as of Q3 2022.6

*Real-world data compiled via Oracle EBS data stored within Kite's Analytics Platform. Data is accurate as of Q3 2022.6

In the ZUMA-3 trial, 6 patients did not receive TECARTUS due to manufacturing failure.1

Global commercial and clinical data in patients with R/R ALL after ≥2 lines of systemic therapy as of February 22, 2023.9

ALL=acute lymphoblastic leukemia; CAR=chimeric antigen receptor; CD=cluster of differentiation; EBS=E-Business Suite; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2024. 2. Witkowski MT, Lasry A, Carroll WL, Aifantis I. Immune-based therapies in acute leukemia. Trends Cancer. 2019;5(10):604-618. 3. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011;17(20):6448-6458. 4. Kochenderfer JN, Rosenberg SA. Treating B‑cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267-276. 5. Mian A, Hill BT. Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. Expert Opin Biol Ther. 2021;21(4):435-441. 6. Data on file [1]. Kite Pharma, Inc; 2022. 7. Data on file [2]. Kite Pharma, Inc; 2022. 8. Data on file [3]. Kite Pharma, Inc; 2022. 9. Data on file. Kite Pharma, Inc; 2023.